

Application No.: 09/585,925  
 Art Unit: 1824

-2-


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claims 1- 15 (Cancelled)

Claim 16 (Currently Amended): A compound represented by the following structural formula:



or physiologically acceptable salts thereof, wherein:

ring A is substituted with suitable substituents or unsubstituted;

Q is  $-N=$  or  $-CR^2=$ ;

X is S, O or  $NOR^3$ ;

Y is  $-S-$ ,  $-SO-$  or  $-SO_2-$ ;

R and  $R^1$  are each, independently, hydrogen, an unsubstituted aliphatic or an aliphatic substituted with suitable substituents, aromatic, heteroaromatic or aralkyl group;

$R^2$  is  $-H$  or a substituent;

$R^3$  is  $-H$  or  $-C(O)R^4$ ;

$R^4$  is a substituted with suitable substituents or unsubstituted aliphatic or aromatic group;

n is 0 or 1; and wherein


when X is S or  $NOR^3$ , R is an optionally substituted with suitable substituents aromatic or aralkyl group and  $R^1$  is hydrogen or a substituted with suitable substituents or unsubstituted aliphatic group;

when X is O and n is 0,  $R^1$  is hydrogen or a substituted with suitable substituents or unsubstituted aliphatic group and R is a substituted with suitable substituents or unsubstituted aromatic or aralkyl group, provided that R is not 2-thienyl, benzoxadiazolyl, 4-oxo-4H-1-benzopyran-3-yl, 6-chloro-4-oxo-4H-1-benzopyran-3-yl, 6-

Application No.: 09/585,925  
Art Unit: 1624


-3-

~~methyl 4-oxo-4H-1-benzopyran-3-yl, 6-acetyloxy 4-oxo-4H-1-benzopyran-3-yl, naphthyl, 3-furanyl, 2-furanyl, 2-pyridyl, 3-pyridinyl, 4-pyridyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 4-acetyloxy-3-methoxyphenyl, 3,5-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3,5-*t*-butyl-4-hydroxyphenyl, 3,5-*i*-propyl-4-hydroxyphenyl, 3-(2-hydroxyphenyl)-1H-pyrazol-4-yl, 3-(5-chloro-2-hydroxyphenyl)-1H-pyrazol-4-yl, or~~





where  $R^{14}$  is H, ~~*p*-F, *o*-Cl, *p*-Cl, *p*-Br, *m*-Br, *o*-CH<sub>3</sub>, *p*-CH<sub>3</sub>, *p*-OCH<sub>2</sub>CH<sub>3</sub>, *O*-Benzyl, CF<sub>3</sub>, phenyl, -OCH<sub>3</sub>, -O-phenyl, NO<sub>2</sub> or, -OC(O)CH<sub>3</sub>, -OCH<sub>2</sub>C(O)C<sub>2</sub>H<sub>5</sub>, -OCH<sub>2</sub>C(O)NHNH<sub>2</sub>, *p*-(O-(CH<sub>2</sub>)<sub>5</sub>-N(CH<sub>2</sub>)<sub>3</sub>), *p*-(O-(CH<sub>2</sub>)<sub>3</sub>-N(*n*-C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>), *p*-(3-piperidin-1-yl-propan-1-oxy), *m*-(2-morpholin-4-yl-ethan-1-oxy), or *m*-(4-(4-ethyl-piperazin-1-yl)-butan-1-oxy); and~~

when X is O and n is 1,  $R^1$  is H or a substituted with suitable substituents or unsubstituted aliphatic group and R is a substituted with suitable substituents or unsubstituted aromatic or aralkyl group, provided that R is not ~~4-nitro-2-methoxyphenyl, 4-methoxy-2-nitrophenyl, 4-chloro-2-nitrophenyl, 2,5-dichlorophenyl, or~~




where  $R^{15}$  is H, Cl, ~~*p*-NO<sub>2</sub>, *o*-NO<sub>2</sub>, *p*-OCH<sub>3</sub>, *o*-CO<sub>2</sub>H, CH<sub>3</sub> or CF<sub>3</sub>~~; and  
provided that the compound is not




Application No.: 09/585,925  
Art Unit: 1624

-4-



Application No.: 09/585,925  
Art Unit: 1624

-5-



2-(4-Acetoxy-3,5-dimethylbenzylidene)-3,4-dihydro-3-oxo-2H-1,4-benzothiazine.

2-(5-tert.-Butyl-3-dimethylaminomethyl-4-hydroxybenzylidene)-3,4-dihydro-3-oxo-2H-1,4-benzothiazine.

2-[5-tert.-Butyl-3-[1,1-dimethyl-2-(tetrahydropyran-2-yloxy)ethyl]-4-hydroxy- $\alpha$ -(tetrahydropyran-2-yloxy)benzyl]-3,4-dihydro-3-oxo-2H-1,4-benzothiazine.

2-(4-Chlorophenylmethylidene)-2H-1,4-benzothiazine-3(4H)-one.

2-(2,4-dichlorophenylmethylidene)-2H-1,4-benzothiazine-3(4H)-one.


2-(4-methoxyphenyl)-2,3-dihydro-5-(2-dimethylaminoethyl)-1,5-benzothiazepine-3,4(5H)-dione hydrochloride.

2[[4-3-(Dimethylamino)propoxy]phenyl]methylene]-2H-1,4-benzothiazin-3(4H)-one.

2-[[4-[2-(Dimethylamino)ethoxy]phenyl]methylene]-2H-1,4-benzothiazin-3(4H)-one. or

Application No.: 09/585,925  
Art Unit: 1624

-6-




Claim 17 (Original): A compound of Claim 16, wherein the aromatic group and the aromatic portion of the aralkyl group defined for R is a heteroaryl group.

Claim 18 (Original): A compound of Claim 17 wherein n is 0 and R is selected from the group consisting of substituted or unsubstituted indole, pyrrole, 7-azaindole, pyrazole, imidazole and indazole.

Claim 19 (Original): A compound of Claim 16, wherein n is 1 and R is selected from the group consisting of substituted or unsubstituted indole, pyrazolyl, phenyl, triazolyl, pyridyl and indazolyl.

Claim 20 (Previously Amended): A compound of Claim 18, wherein Q is CH<sub>2</sub>; Y is S; and R is selected from the group consisting of substituted or unsubstituted pyrrole, pyrazole,



imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, tetrazole, indole, 7-azaindole, indazole, purine, pyrrolo-pyrimidine, pyrazolo-pyrimidine, imidazo-pyridine, imidazo-pyrimidine, imidazo-pyridine, pyrrolo-pyridine, pyrrolo-pyrimidine, pyrrolo-quinoline, pyrrolo-pyrazine, and 6,7,8,9-tetrahydropyrindo-indole.

Claim 21 (Previously Amended): A compound according to Claim 20, wherein R is selected from the group consisting of substituted or unsubstituted pyrrole, pyrazole, imidazole,

Application No.: 09/585,925  
Art Unit: 1624

-7-

oxazole, isoxazole, thiazole, isothiazole, triazole, tetrazole, indole, 7-azaindole, indazole, purine, pyrrolo[2,3-d]pyrimidine, pyrazolo[3,4-d]pyrimidine, imidazo[4,5-d]pyridine, imidazo[1,2-a]pyrimidine, imidazo[1,2-a]pyridine, pyrrolo[3,2-b]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[2,3-c]pyridine, pyrrolo[3,2-b]quinoline, pyrrolo[2,3-b]pyrazine, and 6,7,8,9-tetrahydropyrido[1,2-a]indole.

Claim 22 (Original) A compound of Claim 21 wherein R is optionally substituted with one or more moieties selected from the group consisting of halogens, trihalomethyl, cyano, hydroxy, nitro,  $-NR^5R^6$ , carbamoyl, carboxy, carboxamidoxime,  $-SO_2NR^5R^6$ ,  $-NHSO_2R^5$ ,  $R^7-O-R^8$ ,  $R^7-O-R^8-O-R^9$ ,  $R^{11}$ ,  $R^{11}O$ ,  $R^{11}OC(O)-$ ,  $R^{11}N(R^5)C(O)-$ ,  $R^{11}C(O)-$ ,  $R^{11}C(O)O$ ,  $R^{11}S$ ,  $R^{11}S(O)-$ ,  $R^{11}S(O)_2$ ,  $(R^5R^6)NC(O)-$ ,  $R^{11}(R^5)NC(O)N(R^5)-$ ,  $R^{11}C(O)N(R^5)-$ ,  $R^{12}(CH_2)_m$ ,  $R^{12}(CH_2)_mC(O)N(R^5)-$ ,  $R^{12}(CH_2)_mO$ ,  $R^{12}(CH_2)_mN(R^5)-$ ,  $[R^{12}(CH_2)_m]_2CH-O-(CH_2)_m$ ,  $R^{12}(CH_2)_mOC(O)-$ ,  $R^{12}(CH_2)_mN(R^5)C(O)-$ ,  $R^{12}(CH_2)_mCH(R^{12})(CH_2)_m$ ,  $R^{12}(CH_2)_mC(O)O$ ,  $R^{12}(CH_2)_mN(R^5)C(O)O$ ,  $R^{12}(CH_2)_mOC(O)N(R^5)-$ ,  $R^{12}(CH_2)_mOC(O)O$ ,  $R^{12}(CH_2)_mN(R^5)C(O)(CH_2)_m$ ,  $R^{12}(CH_2)_mOC(O)(CH_2)_m$ ,  $R^{12}(CH_2)_m(CR^5R^6)_m(CH_2)_mN(R^5)(CH_2)_m$ ,  $R^{12}(CH_2)_mC(O)-$ ,  $R^{12}C(O)(CH_2)_m$ ,  $R^{12}(CH_2)_m(CR^5R^6)_m(CH_2)_mN(R^5)C(O)(CH_2)_m$ ,  $R^{12}(CH_2)_m(CR^5R^6)_m(CH_2)_mN(R^5)(CH_2)_mC(O)-$ ,  $[R^{12}(CH_2)_m]_2NC(O)(CH_2)_m$ ,  $R^{12}(CH_2)_mC(O)-$ ,  $R^{12}(CH_2)_m(CR^5R^6)_m(CH_2)_mN(R^5)SO_2-$ ,  $R^{12}(CH_2)_m(CR^5R^6)_m(CH_2)_mO(CH_2)_m$ ,

wherein:

$R^5$  and  $R^6$  for each occurrence are each independently selected from the group consisting of hydrogen, a lower alkyl, benzyl, heteroarylmethyl and aryl group optionally substituted with a halogen, cyano or hydroxy group;

$R^7$  for each occurrence is independently selected from the group consisting of hydrogen,  $R^{10}C(O)-$ , a lower alkyl and an aryl group optionally substituted with one or more halogens, cyano, hydroxy or  $-NR^5R^6$ ;

$R^8$  and  $R^9$  for each occurrence are each independently selected from the group consisting of  $-C(O)-$ , a lower alkyl or an aryl group optionally substituted with one or more halogens, cyano, hydroxy or  $-NR^5R^6$ ;

Application No.: 09/585,925  
Art Unit: 1624

-8-

$R^{10}$  for each occurrence is independently selected from a group consisting of a lower alkyl and an aryl group optionally substituted with one or more halogens, cyano, hydroxy or  $-NR^5R^6$ ;

$R^{11}$  for each occurrence is independently hydrogen or selected from an optionally substituted group consisting of a lower alkyl group, a saturated or unsaturated heterocyclic ring, an aryl group and an aralkyl group, where said groups are optionally substituted with one or more halogens, cyano, hydroxy or  $-NR^5R^6$ ;

$R^{12}$  for each occurrence is independently selected from the group consisting of halogen, carboxy, carbamoyl, lower alkyloxycarbonyl, lower alkenyl, hydroxy, a lower alkyloxy, a lower alcanoyloxy, and  $-NR^5R^6$ ; or is selected from an optionally substituted group consisting of morpholine, piperazine, piperidine, pyrrolidine, homopiperazine, pyridine, triazole, tetrazole, imidazole and tetrahydropyran, where said groups are optionally substituted with one or more hydroxy, lower alkyl, lower alkyloxy, lower hydroxyalkyl, lower aminoalkyl, lower alkyloxyalkyl, a saturated or unsaturated heterocyclic ring, cycloalkyl or  $-NR^5R^6$  group; and

m is independently an integer from 0 to 4.

Claim 23 (Original): A compound of Claim 22, wherein X is O and n is 0.

Claim 24 (Original): A compound of Claim 22, wherein X is S.

Claim 25 (Original): A compound of Claim 22, wherein X is  $NOR_3$ .

Claim 26 (Original): A compound of Claim 23 wherein R is selected from the group consisting of:

pyrrol-2-yl,  
5-methylpyrrol-2-yl,  
3,5-dimethylpyrrol-2-yl,  
4,5-dimethylpyrrol-2-yl,  
4-ethyl-3,5-dimethylpyrrol-2-yl,  
4-ethoxycarbonyl-3,5-dimethylpyrrol-2-yl,  
1-methylpyrrol-2-yl,  
1-(4-hydroxybutyl)pyrrol-2-yl,

Application No.: 09/585,925  
Art Unit: 1624

-9-

1-(2-hydroxyethyl)pyrrol-2-yl,  
1-(3-dimethylaminopropyl)pyrrol-2-yl,  
4-bromopyrrol-2-yl,  
1-[N-(2-morpholinoethyl)carbamoylethyl]pyrrol-2-yl,  
1-(ethoxycarbonylmethyl)pyrrol-2-yl,  
1-(carboxymethyl)pyrrol-2-yl,  
1-[N-(3-dimethylaminopropyl)carbamoylethyl]pyrrol-2-yl,  
1-[(4-methylpiperazin-1-yl)carbamoylethyl]pyrrol-2-yl,  
indol-3-yl,  
1-(4-hydroxybutyl)indol-3-yl,  
5-methoxyindol-3-yl,  
1-(2-hydroxyethoxymethyl)indol-3-yl,  
1-(3-dimethylaminopropyl)indol-3-yl,  
6-methoxycarbonylindol-3-yl,  
2-methylindol-3-yl,  
1-methylindol-3-yl,  
1-isopropylindol-3-yl,  
1-(2-hydroxy-3-dimethylaminopropyl)indol-3-yl,  
5-hydroxyindol-3-yl,  
6-carboxyindol-3-yl,  
5-amino-2-methylindol-3-yl,  
6-(2-dimethylaminoethoxycarbonyl)indol-3-yl,  
6-(2-morpholinoethoxycarbonyl)indol-3-yl,  
6-(3-dimethylaminopropylcarbamoylethyl)indol-3-yl,  
1-(carbamoylethyl)indol-3-yl,  
8-hydroxymethyl-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl,  
1-(ethoxycarbonylmethyl)indol-3-yl,  
4-methoxycarbonylindol-3-yl,  
1-(2-ethoxycarbonylethyl)indol-3-yl,  
7-methoxycarbonylindol-3-yl,  
2-ethoxycarbonylindol-3-yl,  
1-cyclopentylindol-3-yl,



Application No.: 09/585,925  
Art Unit: 1624

-10-

1-(3-tetrahydrofuranyl)indol-3-yl,  
6-(N,N-dimethylaminosulfonyl)indol-3-yl,  
5-(acetylaminomethyl)indol-3-yl,  
1-(diethylcarbamoyl)indol-3-yl,  
5-hydroxy-1-methylindol-3-yl,  
6-methoxyindol-3-yl,  
6-hydroxyindol-3-yl,  
6-[2-(pyrrolidin-1-yl)ethyloxycarbonyl]indol-3-yl,  
6-(2-dimethylaminoethyloxycarbonyl)-1-methylindol-3-yl,  
6-(3-dimethylaminopropylloxycarbonyl)indol-3-yl,  
6-carboxy-1-(2-hydroxyethyl)indol-3-yl,  
6-{N-[2-(pyrrolidin-1-yl)ethyl]carbamoyl}indol-3-yl,  
6-[N-(2-morpholinoethyl) carbamoyl]indol-3-yl,  
6-[N-(2-dimethylaminoethyl)carbamoyl]indol-3-yl,  
6-{N-[3-(4-methylpiperazin-1-yl)propyl]carbamoyl}indol-3-yl,  
6-{N-[2-(piperidin-1-yl)ethyl]carbamoyl}indol-3-yl,  
6-[N-(2-dimethylaminopropyl)carbamoyl]indol-3-yl,  
6-{[N-(2-dimethylaminoethyl)-N-methyl]carbamoyl}indol-3-yl ,  
6-[(4-methylpiperazin-1-yl)carbonyl]indol-3-yl,  
5-[2-(piperidin-1-yl)ethyloxy]indol-3-yl,  
5-(3-dimethylaminopropylloxy)indol-3-yl,  
5-(2-morpholinoethyloxy) indol-3-yl,  
5-(3-dimethylaminopropylloxy)-1-(isopropylloxycarbonyl)indol-3-yl,  
5-(3-dimethylaminopropylloxy)-1-methylindol-3-yl,  
5-(2-morpholinoethyloxy)-1-methylindol-3-yl,  
5-[2-(pyrrolidin-1-yl)ethyloxy]indol-3-yl,  
5-(2-dimethylaminoethyloxy)indol-3-yl,  
6-(3-dimethylaminopropylloxy)indol-3-yl,  
6-(2-morpholinoethyloxy)indol-3-yl,  
6-[2-(piperidin-1-yl)ethyloxy]indol-3-yl,  
6-[2-(pyrrolidin-1-yl)ethyloxy]indol-3-yl,  
6-(2-dimethylaminoethyloxy)indol-3-yl,

Application No.: 09/585,925  
Art Unit: 1624

-11-

6-[(2-dimethylamino-2-methyl)propyloxy]indol-3-yl,  
6-[2-(1-methylpyrrolidin-2-yl)ethyloxy]indol-3-yl,  
6-[2-(1-methylpiperidin-3-yl)methyloxy]indol-3-yl,  
7-(dimethylaminomethyl)-6-hydroxyindol-3-yl,  
7-(dimethylaminomethyl)-6-(2-morpholinoethyloxy)indol-3-yl,  
2-methyl-5-(N'-ethylureido)indol-3-yl,  
2-methyl-5-(p-toluensulfonylamino)indol-3-yl,  
6-[(3-dimethylaminopropyl)aminomethyl]indol-3-yl,  
6-[(2-methoxyethyl)aminomethyl]indol-3-yl,  
1-(carboxymethyl)indol-3-yl,  
1-[N-(2-morpholinoethyl)carbamoylmethyl]indol-3-yl,  
1-[N-(2-methoxyethyl)carbamoylmethyl]indol-3-yl,  
1-[N-(3-dimethylaminopropyl)carbamoylmethyl]indol-3-yl,  
1-[N-(2-(2-pyridyl)ethyl)carbamoylmethyl]indol-3-yl,  
1-[N-[2-(pyrrolidin-1-yl)ethyl]carbamoylmethyl]indol-3-yl,  
7-[N-(3-dimethylaminopropyl)carbamoyl]indol-3-yl,  
1-[4-methylpiperazin-1-yl]carbonylmethyl]indol-3-yl,  
1-[N,N-bis(2-N',N'-diethylaminoethyl)carbamoylmethyl]indol-3-yl,  
1-[4-piperidinopiperidin-1-yl]carbonylmethyl]indol-3-yl,  
1-[N-(2-N',N'-diethylaminoethyl)-N-methyl]carbamoylmethyl]indol-3-yl,  
7-carboxyindol-3-yl,  
7-[4-methylpiperazin-1-yl]carbonyl]indol-3-yl,  
7-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}indol-3-yl,  
7-azaindol-3-yl,  
1-(4-hydroxybutyl)-7-azaindol-3-yl,  
1-(2-hydroxyethyloxymethyl)-7-azaindol-3-yl,  
1-(3-dimethylaminopropyl)-7-azaindol-3-yl,  
1-(2-morpholinoethyl)-7-azaindol-3-yl,  
1-(4-acetoxybutyl)-7-azaindol-3-yl,  
1-(2-hydroxyethyl)-7-azaindol-3-yl,  
1-methyl-7-azaindol-3-yl,  
1-methoxymethyl-7-azaindol-3-yl,

Application No.: 09/585,925  
Art Unit: 1624

-12-

1-(2-dimethylaminomethyl)-7-azaindol-3-yl,  
1-(ethoxycarbonylmethyl)-7-azaindol-3-yl,  
1-[N-(2-morpholinoethyl)carbamoylmethyl]-7-azaindol-3-yl,  
1-carboxymethyl-7-azaindol-3-yl,  
1-{N-[3-(4-methylpiperazin-1-yl)propyl]carbamoylmethyl}-7-azaindol-3-yl,  
1-[(4-methylpiperazin-1-yl)carbamoylmethyl]-7-azaindol-3-yl,  
1-{[N-(2-N',N'-diethylaminoethyl)-N-methyl]carbamoylmethyl}-7-azaindol-3-yl,  
1-{[N-(1-ethylpyrrolidin-2-yl)methyl]carbamoylmethyl}-7-azaindol-3-yl,  
1-[(4-methylhomopiperazin-1-yl)carbonylmethyl]-7-azaindol-3-yl,  
1-[(4-ethylpiperazin-1-yl)carbonylmethyl]-7-azaindol-3-yl,  
1-[(4-piperidinopiperidin-1-yl)carbonylmethyl]-7-azaindol-3-yl,  
1-[N,N-bis(2-N',N'-diethylaminoethyl)carbamoylmethyl]-7-azaindol-3-yl,  
7-benzyloxy pyrrolo[2,3-c]pyridin-5-yl,  
7-hydroxy pyrrolo[2,3-c]pyridin-5-yl,  
1-(2-dimethylaminoethyl)-7-hydroxy pyrrolo[2,3-c]pyridin-5-yl,  
imidazol-2-yl,  
4-trifluoromethylimidazol-2-yl,  
4-cyanoimidazol-2-yl,  
1-methyl-1H-benzo[d]imidazol-2-yl,  
imidazol-5-yl,  
4(5)-methylimidazol-5(4)-yl,  
2-methylimidazol-5-yl,  
2-ethyl-4(5)-methylimidazol-5(4)-yl,  
3-(2-diethylaminoethyl)-4-methylimidazol-5-yl,  
1-(2-diethylaminoethyl)-4-methylimidazol-5-yl,  
1-(2-morpholinoethyl)-4-methylimidazol-5-yl,  
3-(2-morpholinoethyl)-4-methylimidazol-5-yl,  
1-methyl-2-methylthioimidazol-5-yl,  
4(5)-methoxycarbonylimidazol-5(4)-yl,  
4(5)-hydroxymethylimidazol-5(4)-yl,  
furan-3-yl,  
thien-3-yl,

Application No.: 09/585,925  
Art Unit: 1824

-13-

3-methylpyrazol-4-yl,  
3-phenylpyrazol-4-yl,  
1-(2-diethylaminoethyl)-3-methylpyrazol-4-yl,  
1-(2-diethylaminoethyl)-5-methylpyrazol-4-yl,  
1-(2-morpholinoethyl)-3-methylpyrazol-4-yl,  
1-(2-morpholinoethyl)-5-methylpyrazol-4-yl,  
1-methylpyrazol-4-yl,  
1-tert-butylpyrazol-4-yl,  
1-ethoxycarbonylmethyl-3-methylpyrazol-4-yl,  
1-ethoxycarbonylmethyl-5-methylpyrazol-4-yl,  
1-carboxymethyl-3-methylpyrazol-4-yl,  
1-carboxymethyl-5-methylpyrazol-4-yl,  
1-[N-(2-dimethylaminoethyl)carbamoylmethyl]-3-methylpyrazol-4-yl,  
1-[N-[3-(4-methylpiperazin-1-yl)propyl]carbamoylmethyl]-3-methylpyrazol-4-yl,  
1-[N-(2-dimethylaminoethyl)carbamoylmethyl]-5-methylpyrazol-4-yl,  
1-[N-(2-morpholinoethyl)carbamoylmethyl]-3-methylpyrazol-4-yl,  
1-[(4-piperidinopiperidin-1-yl)carbonylmethyl]-3-methylpyrazol-4-yl,  
1-[[N-(2-N',N'-diethylaminoethyl)-N-methyl]carbamoylmethyl]-3-methylpyrazol-4-yl,  
1-[(4-methylpiperazin-1-yl)carbonylmethyl]-5-methylpyrazol-4-yl,  
1-[(4-methylpiperazin-1-yl)carbonylmethyl]-3-methylpyrazol-4-yl,  
1-[N-[3-(imidazol-1-yl)propyl]carbamoylmethyl]-3-methylpyrazol-4-yl,  
1-[[4-(2-hydroxyethyl)piperazin-1-yl]carbonylmethyl]-5-methylpyrazol-4-yl,  
1-[[4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl]carbonylmethyl]-5-methylpyrazol-4-yl,  
indol-2-yl,  
pyrrol-3-yl,  
indazol-3-yl,  
thiazol-2-yl,  
pyrazol-3-yl,  
5(3)-ethoxycarbonylpyrazol-3(5)-yl,  
5(3)-[N-(2-morpholinoethyl)carbamoyl]pyrazol-3(5)-yl,  
5(3)-[N-(2-methoxyethyl)carbamoyl]pyrazol-3(5)-yl,  
5(3)-[N-[2-(pyrrolidin-1-yl)ethyl]carbamoyl]pyrazol-3(5)-yl,

Application No.: 09/585,925  
Art Unit: 1624

-14-

5(3)-[N-(3-dimethylaminopropyl)carbamoyl] pyrazol-3(5)-yl,  
2-(dimethylamino)thiazol-5-yl,  
indol-4-yl,  
3-(morpholinomethyl)indol-4-yl,  
indol-7-yl,  
3-(dimethylaminomethyl)indol-7-yl,  
3-(morpholinomethyl)indol-7-yl,  
3-(piperidinomethyl)indol-7-yl,  
3-[(4-methylpiperazin-1-yl)methyl]indol-7-yl,  
3,5-dimethyl-4-dimethylaminomethylpyrrol-2-yl,  
4-carboxyimidazol-2-yl,  
7-{N-[3-(imidazol-1-yl)propyl]carbamoyl}indol-3-yl,  
7-{N-[3-(4-methylpiperazin-1-yl)propyl]carbamoyl}indol-3-yl,  
7-[N-(2-dimethylaminopropyl)carbamoyl]indol-3-yl,  
7-{N-[2-(pyrrolidin-1-yl)ethyl]carbamoyl}indol-3-yl,  
7-[(4-ethylpiperazin-1-yl)carbonyl]indol-3-yl,  
7-[(4-methylhomopiperazin-1-yl)carbonyl]indol-3-yl,  
3-{[4-(2-hydroxyethyl)piperazin-1-yl]methyl}indol-7-yl,  
3-{[4-(4-hydroxypiperidin-1-yl)methyl]indol-7-yl},  
1-{[(piperazin-1-yl)carbonylmethyl]-7-azaindol-3-yl},  
1-{[(piperazin-1-yl)carbonylmethyl]indol-3-yl},  
1-{[(piperazin-1-yl)carbonylmethyl]-3-methyl-1H-pyrazol-4-yl},  
1-{N-[2-(pyrrolidin-1-yl)ethyl]carbamoylmethyl]-3-methyl-1H-pyrazol-4-yl},  
1-[N-(2-dimethylaminopropyl)carbamoylmethyl]-3-methyl-1H-pyrazol-4-yl,  
3-(2-dimethylaminoacetyl)indol-7-yl,  
6-{(2-morpholinoethyl)aminomethyl}indol-3-yl,  
6-{[2-(pyrrolidin-1-yl)ethyl]aminomethyl}indol-3-yl,  
6-{(3-methoxycarbonylpropyl)oxy}indol-3-yl,  
6-{[(3-(4-methylpiperazin-1-yl)carbonyl]propyloxy}indol-3-yl,  
6-{3-[N-(2-dimethylaminoethyl)-N-methylcarbamoyl]propyloxy}indol-3-yl,  
6-{(2-hydroxyethyl)oxymethyloxy}indol-3-yl,  
6-{3-[(4-piperidinopiperidin-1-yl)carbonyl]propyloxy}indol-3-yl,

Application No.: 09/585,925  
Art Unit: 1624

-15-

6-{3-[[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]propyloxy}indol-3-yl,  
6-[(4-methylpiperazin-1-yl)methyl]indol-3-yl,  
6-{[N-(2-dimethylaminoethyl)-N-methyl]aminomethyl}indol-3-yl,  
7-(dimethylaminomethyl)-6-(2-methoxyethyloxy)indol-3-yl,  
7-(dimethylaminomethyl)-6-(3-methoxycarbonylpropyloxy)indol-3-yl,  
7-(dimethylaminomethyl)-6-{{3-(4-methylpiperazin-1-yl)carbonyl}propyloxy}indol-3-yl,  
7-(dimethylaminomethyl)-6-[(2-hydroxyethyl)oxymethyloxy]indol-3-yl,  
6-(2-methoxyethyloxy)-7-[(pyrrolidin-1-yl)methyl]indol-3-yl,  
6-{{3-(4-methylpiperazin-1-yl)carbonyl}propyloxy}-7-[(pyrrolidin-1-yl)methyl]indol-3-yl,  
6-[(2-hydroxyethyl)oxymethyloxy]-7-[(pyrrolidin-1-yl)methyl]indol-3-yl,  
7-[[[(pyrrolidin-1-yl)methyl]-6-{[2-(pyrrolidin-1-yl)ethyl]oxy}]indol-3-yl,  
6-[2-(pyrrolidin-1-yl)ethyloxy]-7-azaindol-3-yl,  
6-(2-piperidinoethyloxy)-7-azaindol-3-yl,  
6-[(2-dimethylamino-2-methyl)propyloxy]-7-azaindol-3-yl,  
6[(2-hydroxyethyl)aminomethylcarbonyl]indol-3-yl,  
6-{{2-(pyrrolidin-1-yl)ethyl]aminomethylcarbonyl}indol-3-yl,  
6-[(2-diethylaminoethyl)aminomethylcarbonyl]indol-3-yl,  
4-carbamoylimidazol-2-yl,  
4(5)-methyl-2-(methylmercapto)imidazol-5(4)-yl,  
4(5)-methyl-2-(methylsulfonyl)imidazol-5(4)-yl,  
2-amino-4(5)-methylimidazol-5(4)-yl,  
4(5)-dimethylaminomethylimidazol-5(4)-yl,  
4(5)-methylaminomethylimidazol-5(4)-yl,  
4(5)-diethylaminomethylimidazol-5(4)-yl,  
6-(N-methylaminosulfonyl)indol-3-yl,  
6-[N-(3-dimethylaminopropyl)sulfonyl]indol-3-yl,  
6-{N-[2-(pyrrolidin-1-yl)ethyl]aminosulfonyl}indol-3-yl,  
6-{N-[2-piperidinoethyl]aminosulfonyl}indol-3-yl,  
6-[N-(2-morpholinoethyl)aminosulfonyl]indol-3-yl,  
6-{N-[2-(piperidinomethyl)aminosulfonyl}indol-3-yl,  
6-{N-[3-(4-methylpiperazin-1-yl)propyl]aminosulfonyl}indol-3-yl,

Application No.: 09/585,925  
Art Unit: 1624

-16-

7-[N-(2-morpholinoethyl)carbamoyl]indol-3-yl,  
7-[N-(2-piperidinoethyl)carbamoyl]indol-3-yl,  
7-{{N-(2-N',N'-diethylaminoethyl)-N-methyl}carbamoyl} indol-3-yl,  
7-[N-(2-methoxyethyl)carbamoyl]indol-3-yl,  
7-[(4-piperidinopiperidin-1-yl)carbonyl]indol-3-yl,  
7-[(piperazin-1-yl)carbonyl]indol-3-yl,  
7-{N-[(2,2,N',N'-tetramethyl)propyl]carbamoyl}indol-3-yl,  
7-{N-[(1-ethylpyrrolidin-2-yl)methyl]carbamoyl}indol-3-yl,  
7-{N-[2-(2-pyridyl)ethyl]carbamoyl}indol-3-yl,  
6-{N-[2-(2-pyridyl)ethyl]carbamoyl}indol-3-yl,  
6-[(4-piperidinopiperidin-1-yl)carbonyl]indol-3-yl,  
6-[(piperazin-1-yl)carbonyl]indol-3-yl,  
6-{N-[(2,2,N',N'-tetramethyl)propyl]carbamoyl}indol-3-yl,  
6-{N-[(1-ethylpyrrolidin-2-yl)methyl]carbamoyl}indol-3-yl,  
6-[(4-methylhomopiperazin-1-yl)carbonyl]indol-3-yl,  
6-[(4-butylpiperazin-1-yl)carbonyl]indol-3-yl,  
6-[(4-ethylpiperazin-1-yl)carbonyl]indol-3-yl,  
6-[[4-(2-(pyrrolidin-1-yl)ethyl)piperidin-1-yl]carbonyl]indol-3-yl,  
6-{{N-(3-dimethylamino)prop-2-yl}carbamoyl}indol-3-yl,  
6-{N-[3-(imidazol-1-yl)propyl]carbamoyl}indol-3-yl,  
6-[[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]indol-3-yl,  
3-[(4-ethylpiperazin-1-yl)methyl]indol-7-yl,  
3-[(pyrrolidin-1-yl)methyl]indol-7-yl,  
3-[(4-methylhomopiperazin-1-yl)methyl]indol-7-yl,  
3-(diethylaminomethyl)indol-7-yl,  
3-{{N-(2-N',N'-dimethylaminoethyl)-N-methyl}aminomethyl}indol-7-yl,  
3-[(4-piperidinopiperidin-1-yl)methyl]indol-7-yl,  
3-(2-piperidinoacetyl)indol-7-yl,  
3-[2-(pyrrolidin-1-yl)acetyl]indol-7-yl,  
3-(2-diethylaminoacetyl)indol-7-yl,  
3-[2-(4-methylpiperazin-1-yl)acetyl]indol-7-yl,  
3-[2-(4-methylhomopiperazin-1-yl)acetyl]indol-7-yl,

Application No.: 09/585,925  
Art Unit: 1624

-17-

3-(2-morpholinoacetyl)indol-7-yl,  
3-{2-[(2-methoxyethyl)amino]acetyl}indol-7-yl,  
3-{2-[(2-piperidinoethyl)amino]acetyl}indol-7-yl,  
3-{2-[[3-(imidazol-1-yl)propyl]amino]acetyl}indol-7-yl,  
6-[3-(carboxypropyl)oxy]indol-3-yl,  
6-{3-[(4-methylhomopiperazin-1-yl)carbonyl]propyloxy}indol-3-yl,  
6-[(2-homopiperidin-1-yl)ethyloxy]indol-3-yl,  
6-[(2-diethylamino-1-methyl)ethyloxy]indol-3-yl,  
6-{2-[(tetrahydropyran-2-yl)oxy]ethyloxy}indol-3-yl,  
6-[(2-hydroxyethyl)oxy]indol-3-yl,  
6-[2-(isopropoxyloxy)ethyloxy]indol-3-yl,  
6-[2-(methoxyethyl)oxy]indol-3-yl,  
6-[(3-methoxypropyl)oxy]indol-3-yl,  
6-[(3-methoxybutyl)oxy]indol-3-yl,  
6-[[N,N-diethylcarbamoyl)methyl]oxy}indol-3-yl,  
7-[2-(piperidin-1-yl)ethyloxy]indol-3-yl,  
7-[(2-homopiperidin-1-yl)ethyloxy]indol-3-yl,  
7-[(2-diethylamino-1-methyl)ethyloxy]indol-3-yl,  
7-{2-[(tetrahydropyran-2-yl)oxy]ethyloxy}indol-3-yl,  
7-[(2-hydroxyethyl)oxy]indol-3-yl,  
7-[2-(isopropoxyloxy)ethyloxy]indol-3-yl,  
7-[2-(methoxyethyl)oxy]indol-3-yl,  
7-[(3-methoxypropyl)oxy]indol-3-yl,  
7-[(3-methoxybutyl)oxy]indol-3-yl,  
7-[[N,N-diethylcarbamoyl)methyl]oxy}indol-3-yl,  
7-(dimethylaminomethyl)-6-[(2-piperidin-1-yl)ethyloxy]indol-3-yl,  
7-(dimethylaminomethyl)-6-[(2-homopiperidin-1-yl)ethyloxy]indol-3-yl,  
7-(dimethylaminomethyl)-6-{2-[(tetrahydropyran-2-yl)oxy]ethyloxy}indol-3-yl,  
7-(dimethylaminomethyl)-6-[(2-hydroxyethyl)oxy]indol-3-yl,  
7-(dimethylaminomethyl)-6-[2-(isopropoxyloxy)ethyloxy]indol-3-yl,  
7-(dimethylaminomethyl)-6-[2-(methoxyethyl)oxy]indol-3-yl,  
7-(dimethylaminomethyl)-6-[(3-methoxypropyl)oxy]indol-3-yl,



7-(dimethylaminomethyl)-6-[(3-methoxybutyl)oxy]indol-3-yl,  
7-[(pyrrolidin-1-yl)methyl]-6-[(2-piperidin-1-yl)ethyloxy]indol-3-yl,  
7-[(pyrrolidin-1-yl)methyl]-6-[(2-homopiperidin-1-yl)ethyloxy]indol-3-yl,  
7-[(pyrrolidin-1-yl)methyl]-6-{2-[(tetrahydropyran-2-yl)oxy]ethyloxy}indol-3-yl,  
7-[(pyrrolidin-1-yl)methyl]-6-[(2-hydroxyethyl)oxy]indol-3-yl,  
7-[(pyrrolidin-1-yl)methyl]-6-[2-(isopropoxy)ethyloxy]indol-3-yl,  
7-[(pyrrolidin-1-yl)methyl]-6-[2-(methoxyethyl)oxy]indol-3-yl,  
7-[(pyrrolidin-1-yl)methyl]-6-[(3-methoxypropyl)oxy]indol-3-yl,  
7-[(pyrrolidin-1-yl)methyl]-6-[(3-methoxybutyl)oxy]indol-3-yl,  
6-[(2-homopiperidin-1-yl)ethyloxy]-7-azaindol-3-yl,  
6-[(2-diethylamino-1-methyl)ethyloxy]-7-azaindol-3-yl,  
6-{2-[(tetrahydropyran-2-yl)oxy]ethyloxy}-7-azaindol-3-yl,  
6-[(2-hydroxyethyl)oxy]-7-azaindol-3-yl,  
6-[2-(isopropoxy)ethyloxy]-7-azaindol-3-yl,  
6-[2-(methoxyethyl)oxy]-7-azaindol-3-yl,  
6-[(3-methoxypropyl)oxy]-7-azaindol-3-yl,  
6-[(3-methoxybutyl)oxy]-7-azaindol-3-yl,  
6-[(N,N-diethylcarbamoyl)methyl]oxy}-7-azaindol-3-yl,  
6-{4-(2-hydroxyethyl)piperazin-1-yl}methyl}indol-3-yl,  
6-[(4-methylhomopiperazin-1-yl)]methylindol-3-yl,  
6-[(4-piperidinopiperidin-1-yl)methyl]indol-3-yl,  
6-[[3-(isopropoxy)propyl]aminomethyl}indol-3-yl,  
6-[[3,3-bis(ethyloxy)propyl]aminomethyl}indol-3-yl,  
6-[(2,2-dimethyl-1,3-dioxolane-4-methane)aminomethyl]indol-3-yl,  
6-{3-[(2-methoxyethyl)oxypropyl]aminomethyl}indol-3-yl,  
6-[[3-(ethyloxy)propyl]aminomethyl}indol-3-yl,  
6-[[3-(butyloxy)propyl]aminomethyl}indol-3-yl,  
6-[(3-methoxypropyl)aminomethyl]indol-3-yl,  
6-(chloromethylcarbonyl)indol-3-yl,  
6-[2-(isopropoxyethyl)aminomethylcarbonyl]indol-3-yl,  
6-[[2-(piperidin-1-yl)ethyl]aminomethylcarbonyl}indol-3-yl,  
6-[[2-(homopiperidin-1-yl)ethyl]aminomethylcarbonyl}indol-3-yl,

Application No.: 09/585,925  
Art Unit: 1624

-19-

6-{4-(2-hydroxyethyl)piperazin-1-yl}methylcarbonyl}indol-3-yl,  
6-[[4-methylhomopiperazin-1-yl]]methyl}carbonylindol-3-yl,  
6-[(4-piperidinopiperidin-1-yl)methylcarbonyl]indol-3-yl,  
6-[(3-(isopropoxy)propyl)aminomethylcarbonyl]indol-3-yl,  
6-[(3,3-bis(ethyloxy)propyl)aminomethylcarbonyl]indol-3-yl,  
6-[(2,2-dimethyl-1,3-dioxolane-4-methane)aminomethylcarbonyl]indol-3-yl,  
6-{3-[(2-methoxyethyl)oxypropyl]aminomethylcarbonyl}indol-3-yl,  
6-{3-(ethyloxy)propyl}aminomethylcarbonyl}indol-3-yl,  
6-[3-(butyloxy)propyl]aminomethylcarbonyl]indol-3-yl, or  
6-[(3-methoxypropyl)aminomethylcarbonyl]indol-3-yl.

Claims 27 – 35 (Cancelled)

Claim 36 (Original): A pharmaceutical composition comprising a compound of Claim 16 or a physiologically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

Claim 37 (Previously Presented) The compound which is 2-(1-(4-acetoxybutyl)-7-azaindol-3-yl)methylene-2H-1,4-benzothiazin-3(4H)-one, or a physiologically acceptable salt thereof.

Claim 38 (Previously Presented) A pharmaceutical composition comprising the compound of claim 37, or a physiological salt thereof, and a pharmaceutically acceptable diluent or carrier.